This study focuses on treating Extensive stage small cell lung cancer, a type of lung cancer that has spread to other parts of the body. The purpose of the study is to compare the effectiveness of using tarlatamab combined with durvalumab against using durvalumab alone. Participants may also receive other medications used for support, such as carboplatin, cisplatin, etoposide, dexamethasone, mannitol, argipressin, mycophenolate mofetil, infliximab, siltuximab, tocilizumab, paracetamol, or prednisolone.
The study is designed to see which treatment approach helps patients live longer, which is referred to as overall survival. Other factors being looked at include progression-free survival, which is the length of time during and after treatment that a disease does not get worse, and the time it takes for a disease to begin growing again. The study also monitors how the body responds to the medicine and any changes in symptoms like cough, chest pain, or dyspnea, which is the medical term for shortness of breath.
During the trial, participants are assigned to different groups to receive either the combination of medicines or a single medicine. Researchers will track how the drugs affect the body and any adverse events, which are unexpected or unpleasant side effects that occur during treatment. The study will also examine the amount of medicine present in the blood and how the body’s health and quality of life change over time.
Austria 
Belgium 
Bulgaria 
Czechia 
Denmark 
France 
Germany 
Greece 
Hungary 
Ireland 
Italy 
Poland 
Portugal 
Romania 
Spain 
The Netherlands